Related news in the media


Date: April 19, 2016
Source: University Health Network
Summary: Breast cancer patients undergoing treatment with trastuzumab-containing regimens should be monitored for heart damage regardless of age.

Report casts doubt on SF-area breast cancer ‘cluster’

Study finds risk increases, though, for lesser cardiac conditions

April 21, 2016
Source: Kaiser Permanente
The use of aromatase inhibitors, hormone-therapy drugs used to treat patients with breast cancer, was not associated with an increased risk of fatal cardiovascular events, including heart attacks or stroke, compared with tamoxifen, another commonly prescribed anti-cancer drug that works on hormones and which has been associated with a serious risk of stroke, report investigators.